BRIEF-Corvus Pharmaceuticals Announces Data From Cohort 2 Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis

Reuters
13 Jan

Jan 13 (Reuters) - Corvus Pharmaceuticals Inc :

* CORVUS PHARMACEUTICALS ANNOUNCES DATA FROM COHORT 2 OF PLACEBO-CONTROLLED PHASE 1 CLINICAL TRIAL OF SOQUELITINIB FOR ATOPIC DERMATITIS

* COHORT 2 FULLY ENROLLED, FULL RESULTS EXPECTED IN Q2 2025

* DATA SHOW FAVORABLE SAFETY AND EFFICACY PROFILE

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10